CD63

Across TCGA pan-cancer cohorts, CD63 mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated CD63 data layer compared with 29 for mass-spec protein and 3 for mutation status.

The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where higher CD63 mass-spec protein is associated with worse overall survival. In most high-consensus cancer types, elevated CD63 expression acts as an unfavorable survival marker.

PDAC, COAD, and CCRCC are the cancer types where CD63 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PDAC	OS	Tertile	All	0.416	0.618	.002	77	view →
COAD	DFS	Median	II,III,IV	0.877	1.000	.016	60	view →
CCRCC	DFS	Median	All	0.554	0.898	<.001	38	view →
LUAD	DFS	Quartile	II,III,IV	0.792	1.000	.005	21	view →
LSCC	DFS	Quartile	All	0.585	0.860	.019	3	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

CD63–PDAC (OS)

Open the PDAC breakdown →